Current position

Two Sigma Investments, LP’s Edwards Lifesciences Corp (EW) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Two Sigma Investments, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ4 2015Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares3.07MHighest verified quarter-end share count
Quarters reported16Verified quarters with shares above zero
What happened?

Two Sigma Investments, LP first reported Edwards Lifesciences Corp in Q4 2015. The reported position was increased and reduced across later filings. Two Sigma Investments, LP currently reports 1.52M shares. The latest verified filing showed: Bought 44.7% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 44.7% more+470.36K shares · 1.52M shares reported after the change
Filing context

Quarter-end price $90.46

Q1 2026
Bought 168.7% more+660.15K shares · 1.05M shares reported after the change
Filing context

Quarter-end price $80.08

Q1 2024
Sold 88.8% of the position−1.03M shares · 129.71K shares remained
Filing context

Quarter-end price $95.56

Q4 2023
Sold 10.8% of the position−141.24K shares · 1.16M shares remained
Filing context

Quarter-end price $76.25

Q3 2023
Bought 54.2% more+458.35K shares · 1.30M shares reported after the change
Filing context

Quarter-end price $69.28

Q2 2023
Sold 47.1% of the position−750.81K shares · 844.92K shares remained
Filing context

Quarter-end price $94.33

Portfolio importance

How important is Edwards Lifesciences Corp in Two Sigma Investments, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#225of 5017 reported positions
Peak portfolio weight0.7%Q4 2022
Best historical rank#14Q4 2022
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$88.782026-09-22

Market context only; not an investor transaction price.

Latest filing quarter-end price$90.46Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

Coverage is bounded to the institution’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Two Sigma’s complete trading book, models, short positions, exact trade dates or execution prices. Options are reported separately.